Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

CTNM 11.25.2024

Full Press ReleaseSEC FilingsOur CTNM Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
  • 12.16.2024 - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
  • 12.04.2024 - 7th Annual Evercore HealthCONx Conference

Recent Filings

  • 11.27.2024 - 4 Statement of changes in beneficial ownership of securities
  • 11.18.2024 - 144 Report of proposed sale of securities
  • 11.14.2024 - SC 13G Statement of Beneficial Ownership by Certain Investors

SAN DIEGO--(BUSINESS WIRE)--Nov. 25, 2024--Contineum Therapeutics, Inc.(NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 7th AnnualEvercore HealthCONx ConferenceinMiamionWednesday, December 4, 2024at11:15 a.m. ET.

An audio webcast of the fireside chat can be accessed on theInvestorssection of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307, a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis. PIPE-307 is being developed pursuant to a global license and development agreement betweenContineum and Janssen Pharmaceutica NV, a Johnson & Johnson company, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024. For more information, please visitwww.contineum-tx.com.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241125236974/en/

Steve KunszaboContineum TherapeuticsSenior Director, Investor Relations & Corporate Communications858-649-1158skunszabo@contineum-tx.com

Source:Contineum Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com